Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers. While conventional technologies, such as FISH and PCR, allow accurate low-throughput detection (e.g., EML4-ALK fusion), next-generation sequencing-based approaches enable comprehensive and simultaneous identification of various alterations (single nucleotide variants, insertions/deletions, fusions, copy number alterations) and genomic signatures (microsatellite instability, tumor mutational burden).
Compared to conventional technologies, NGS-based approaches overcome the challenge of limited materials and reduce the turnaround time. However, further improvements are still needed due to the complex structure of the genome, including repetitive regions and high GC/AT content.
In this webinar, Dr. Judith Müller-Eisert of NEO New Oncology will discuss a collaboration with Agilent Technologies to develop several hybrid capture-based assays for various tumor entities using the SureSelect XT HS2 chemistry. She will share details of the kit’s performance and discuss its use as a powerful tool for cancer profiling.
Dr. Müller-Eisert is the leading scientist in the field of molecular profiling at NEO New Oncology. She has more than 10 years of experience in the field of tumor biology, both, in the academic and industrial setting. She holds a Master’s degree in Biology from the University of Mainz and a PhD degree from the University of Würzburg (both located in Germany).
Jeffrey Ku is a Global Product Manager who manages Agilent’s SureSelect library prep portfolio. He has more than 10 years of experience in the NGS field, both in R&D and marketing. He holds a master degree in Biotechnology from Columbia University and a PhD degree in Human Statistical Genetics from Washington University in St. Louis.
For Research Use Only. Not for use in diagnostic procedures.